Structural & Congenital Heart Disease

Patients with atrial fibrillation can safely continue oral anticoagulation (OAC) while undergoing transcatheter aortic valve replacement (TAVR), suggests a retrospective study published Jan. 7 in the American Journal of Cardiology.

Adults with congenital heart disease (CHD) report better health-related quality of life (HRQoL) when treated with surgical or catheter interventions rather than drug therapy or surveillance, according to research published Jan. 8 in the American Journal of Cardiology.

Almost 95 percent of patients survived 25 years after discharge for surgical repair of tetralogy of Fallot without requiring a transplant, according to a U.S. registry study published in JAMA Cardiology. While this statistic highlights the “excellent” outcomes for this congenital heart condition, the report’s authors also identified areas for further improvement.

Developing an effective triage process for patients on the transcatheter aortic valve replacement (TAVR) waitlist could be critical to those patients’ postprocedural outcomes as the intervention continues to gain traction and popularity, researchers reported Jan. 5 in the Journal of the American Heart Association.

The Society of Cardiovascular Computed Tomography (SCCT) released updated guidelines for using CT imaging in patients undergoing transcatheter aortic valve replacement (TAVR).

The first United States patient has been treated with the J-Valve TF system designed to address one of the holes in the rapidly evolving TAVR field: the lack of devices specifically targeting pure aortic regurgitation.

Ramping up the battle against cardiovascular disease in women represents a golden opportunity to move the needle on mortality.

Will operators be able to replicate COAPT’s restraint and its outcomes?

Three more executives resigned from Johns Hopkins All Children’s Hospital in St. Petersburg, Florida, in the continued fallout from an investigation by the Tampa Bay Times that revealed mortality rates tripled over just a few years in the pediatric heart surgery unit.

The Sapien 3 Ultra heart valve has received FDA approval for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are considered to be at intermediate or high risk of open-heart surgery, device manufacturer Edwards Lifesciences announced on Dec. 28.

Publicly posted hospital ratings could be confusing heart patients more than helping them, Reuters reported of a Journal of the American College of Surgeons study that found significant disparities between major rating systems in the U.S.

The severity of left ventricular dysfunction at baseline didn’t appear to impact survival after transcatheter aortic valve replacement (TAVR) in a substudy of patients with low-flow, low-gradient (LFLG) aortic stenosis, suggesting TAVR is an acceptable treatment in this high-risk population.